Isis Pharmaceuticals, Inc. (ISIS) Posts Q2 Loss of 9c/Share

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q2 EPS of ($0.09), $0.12 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $26.76 million.

For earnings history and earnings-related data on Isis Pharmaceuticals, Inc. (ISIS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Goldman Sachs reports global fund inflows for week of July 8
• Piper Sandler on FirstSun Capital Bancorp (FSUN): 'We expect shares to underperform on Friday'